



June 20, 2019

GX Corporation SDN BHD  
Foo Khon Pu  
Managing Director  
LOT 6491, Batu 5 3/4, Sementa, Jalan Kapar  
Klang, 42100 My

Re: K183354

Trade/Device Name: Powder Free Blue Nitrile Examination Gloves - Tested for use with 32  
Chemotherapy Drugs and Fentanyl Citrate

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I

Product Code: LZC, LZA, QDO

Dated: May 13, 2019

Received: May 20, 2019

Dear Foo Khon Pu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For Elizabeth Claverie-Williams, M.S.  
Assistant Director  
THT4B2: Disinfection, Reprocessing and Personal  
Protection  
Acting Assistant Director, THT4B1: Sterility Devices  
DHT4B: Division of Infection Control  
and Plastic Surgery Devices  
OHT4: Office of Surgical  
and Infection Control Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

**Indications for Use**

510(k) Number (if known)  
K183354

**Device Name**

Powder Free Blue Nitrile Examination Gloves - Tested for Use with 32 Chemotherapy Drugs and Fentanyl Citrate

**Indications for Use (Describe)**

A Patient examination glove is a disposable device intended for medical purposes that worn on the examiner's hand or finger to prevent contamination between patient and examiner. Tested for use with chemotherapy drugs as listed below.

Chemotherapy Drug permeation and concentration ( Breakthrough Detection Time) in Minutes. The following chemicals have been tested with these gloves.

Chemotherapy Drugs:	Breakthrough Detection Time in Minutes
1. Carmustine ( BCNU)3.3 mg/ml(3,300 ppm)	54.8 min
2. Cisplatin 1.0 mg/ml (1,000ppm)	>240 min
3. Cyclophosphamide (Cytosan) 20mg/ml(20,000ppm)	>240 min
4. Dacarbazine (DTIC)10.0 mg/ml(10,000ppm)	>240 min
5. Doxorubicin Hydrochloride 2.0 mg/ml (2,000ppm)	>240 min
6. Etoposide (Toposar) 20.0 mg/ml (20,000ppm)	>240 min
7. Fluorouracil 50.0 mg/ml (50,000ppm)	>240 min
8. Ifosfamide 50.0 mg/ml (50,000ppm)	>240 min
9. Methotrexate 25 mg/ml (25,000ppm)	>240 min
10.Mitomycin C 0.5 mg/ml (500ppm)	>240 min
11. Mitoxantrone 2.0 mg/ml (2,000ppm)	>240 min
12. Paclitaxel (Taxol) 6.0 mg/ml (6,000ppm)	>240 min
13. Thio-Tepa 10.0 mg/ml (10,000ppm)	46.9 min
14.Vincristine Sulfate 1.0 mg/ml (1,000ppm)	>240 min
15. Amethopterin (Methotrexate) 25 mg/ml, (25,000 ppm)	>240 min
16. Bleomycin 15 mg/ml (15,000 ppm)	>240 min
17. Busulfan 6 mg/ml (6,000 ppm)	>240 min
18. Carboplatin 10 mg/ml (10,000 ppm)	>240 min
19. Cytarabine 100 mg/ml (100.000 ppm)	>240 min
20. Daunorubicin 5 mg/ml (5,000 ppm)	>240 min
21. Doxetacel 10.0 mg/ml (10,000 ppm)	>240 min
22. Ellence 2 mg/ml (2,000 ppm)	>240 min
23. Fludarabine 25 mg/ml (25,000 ppm)	>240 min
24. Gemcitabine (Gemzar) 38 mg/ml (38,000 ppm)	>240 min
25. Idarubicin 1 mg/ml (1,000 ppm)	>240 min
26. Irinotecan 20.0 mg/ml (20,000 ppm)	>240 min
27. Mechlorethamine HCL 1.0 mg/ml (1,000 ppm)	>240 min
28. Melphalan 5 mg/ml (5,000 ppm)	>240 min
29. Oxaliplatin 2.0 mg.ml (2,000 ppm)	>240 min
30. Rituximab 10 mg/ml (10,000 ppm)	>240 min
31. Trisonex 0.1 mg/ml (100 ppm)	>240 min
32. Vinorelbin 10 mg/ml (10,000 ppm)	>240 min

plus Other Drugs

1. Fentanyl Citrate Injection 100 mcg/2ml	>240min
---	---------

---

Please Note that the following Drugs have extremely low permeation times : Carmustine : 54,8 minutes and Thio-Tepa: 46.9 minutes.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

---

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

---

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*